Etanercept and the Treatment of Multicentric Reticulohistiocytosis

Lovelace, Kelli; Loyd, Aaron; Adelson, David; Crowson, Neil; Taylor, Julia R.; Cornelison, Raymond L.

doi:10.1001/archderm.141.9.1167-b

Cited by 37 publications

(9 citation statements)

References 4 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this patient, combination etanercept 25 mg twice weekly and hydroxychloroquine halted disease progression. In contrast to these successful outcomes, another case in the literature describes a 42-year-old man whose condition failed to respond to oral corticosteroids in combination with etanercept 25 mg or 50 mg twice weekly [71,72,73]. …”

Section: -Multicentric Reticulohistiocytosismentioning

confidence: 99%

Off-Label Dermatological Uses of Etanercept Treatment

2016

J turk acad dermatol

View full text Add to dashboard Cite

Background: Tumor necrosis factor-alpha (TNF-α) is a proinflammatory cytokine that plays an immunomodulatory role in a variety of systemic and dermatologic disease. Its blockade can be achieved by using specific inhibitors like etanercept. At present, etanercept is approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile idiopathic arthritis and psoriasis treatment. However, it has been used with promising results in other inflammatory dermatoses. Etanercept treatment have been reported in the following dermatologic diseases: sarcoidosis, hidradenitis suppurativa, acne vulgaris, cicatricial pemphigoid, pemphigus vulgaris, Hailey-Hailey disease, Behçet' s disease, oral aphthous stomatitis, pyoderma gangrenosum, multicentric reticulohistiocytosis, apthous stomatitis, Sneddon-Wilkinson disease, acrodermatitis continua of Hallopeau, SAPHO syndrome, pityriasis rubra pilaris, vitiligo, necrobiosis lipoidica, silicone granulomas, Sweet's syndrome, atopic dermatitis, dyshidrotic eczema, toxic epidermal necrolysis, alopecia areata, centrifugal annular erythema, primary amyloidosis, erythroderma-related pruritus in Sézary syndrome, cutaneous T-cell lymphoma, inflammatory linear verrucous epidermal nevus, excessive scarring, postherpetic neuralgia, dermatomyositis, vasculitis, lupus erythematosus, and scleroderma. The vast majority of these reports are in the form of individual case reports and small case series. A growing number of published reports suggest that etanercept treatment may be effective in the treatment of numerous inflammatory skin disease outside their currently approved indications.

show abstract

Section: -Multicentric Reticulohistiocytosismentioning

confidence: 99%

Off-Label Dermatological Uses of Etanercept Treatment

2016

J turk acad dermatol

View full text Add to dashboard Cite

show abstract

“…Tumour necrosis factor-α inhibitors, including etanercept, infliximab and leflunomide, have shown good results in recalcitrant cases of MRH (8)(9)(10). Our patient has been well managed with a combination therapy of prednisolone (starting with 8 mg/day, and gradually tapering to 2.5 mg/ day), COX-2 inhibitor (400 mg/day), hydroxychloroquine (400 mg/day) and methotrexate (7.5 mg, once a week).…”

Section: Diagnosis: Multicentric Reticulohistocytosismentioning

confidence: 99%

Papules, Arthralgia, Dry Mouth and Dry Eyes: A Quiz

Jung¹,

Kim²,

Lee³

et al. 2013

Acta Derm Venerol

View full text Add to dashboard Cite

A 59-year-old Korean woman presented with asymptomatic multiple papules on the superior aspect of her ears, the posterior neck and proximal nail-folds of her right thumb and right 3 rd and 4 th fingers for one month (Fig. 1). One month earlier, she visited her GP with a 2-month history of symmetrical polyarthralgia involving the wrists, fingers, shoulders and knees. She was treated with prednisolone, gabapentin and non-steroidal anti-inflammatory drugs for one week with no improvement. She also developed symptoms of dry mouth and dry eyes. She was transferred to the Department of Rheumatology for further evaluation. The results of laboratory examination, systemic lupus erythematosus (SLE) profile studies, radiological examination, ultrasound-guided arthrocentesis, Schirmer's test, salivary gland scan and lip biopsy were not compatible with rheumatoid arthritis or Sjögren's syndrome.The patient was transferred to our clinic for the evaluation and we performed a skin biopsy of a yellow-red papule on the right ear (Fig. 1C).

show abstract

“…24,25 Sellam et al 24 reported 2 cases of MR treated with infliximab, which resulted in dramatic improvement in cutaneous lesions but minimal to no improvement in articular disease. One of the patients was later switched to etanercept therapy, which also failed to improve the joint disease.…”

Section: Commentmentioning

confidence: 99%

“…One of the patients was later switched to etanercept therapy, which also failed to improve the joint disease. Lovelace et al 25 described a patient who failed to improve with etanercept and intramuscular triamcinolone acetonide therapies and postulated that perhaps concomitant treatment with TNF inhibition, methotrexate, and corticosteroids is required for therapeutic success. On review of the relatively small number of previously reported cases of MR treated with TNF blockade, there appears to be a trend toward success in those patients treated simultaneously with TNF inhibition, prednisone, and methotrexate.…”

Section: Commentmentioning

confidence: 99%

“…On review of the relatively small number of previously reported cases of MR treated with TNF blockade, there appears to be a trend toward success in those patients treated simultaneously with TNF inhibition, prednisone, and methotrexate. [20][21][22][23][24][25] While our patient's disease is not in total remission, he experienced a dramatic improvement in both cutaneous and articular manifestations of MR after receiving 3 infusions of infliximab while continuing his prior regimen of methotrexate and prednisone. He has achieved a sustained response, and his skin is nearly clear after 12 months of continued therapy; he attributes his significantly improved quality of life to the addition of infliximab.…”

Section: Commentmentioning

confidence: 99%

See 1 more Smart Citation